sumitomo dainippon pharma co
(4506:Tokyo Stock Exchange)
Mark T. Iwicki
|Age||Total Calculated Compensation||This person is connected to 86 board members in 9 different organizations across 10 different industries.|
See Board Relationships
Mr. Mark T. Iwicki has been the Executive Chairman of Kala Pharmaceuticals, Inc. since June 2015 and serves as its Chief Executive Officer. Mr. Iwicki served as the Chief Executive Officer and President of Civitas Therapeutics, Inc./Civitas Pharmaceuticals since January 29, 2014. He has more than 25 years of experience as a pharmaceutical industry leader managing all stages of drug development in multiple therapeutic areas. He has extensive experience managing high-performance ...
6-8 Doshomachi 2-chomePhone: 81 6 6203 5321
Osaka, -- 541-0045
Fax: 81 6 6202 6028
Board Members Memberships*
Chairman and Member of Compensation Committee
Executive Chairman and Chief Executive Officer
Director and Member of Audit Committee
Loyola University Maryland
Ball State University
Annual Compensation*There is no Annual Compensation data available.
Stock Options*There is no Stock Options data available.
Total Compensation*There is no Total Compensation data available.
The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content.
|There is no Competitor Compensation data available.|
Sponsored Financial Commentaries
Only a company representative may request an update for the company profile. Documentation will be required.